GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Fred Saad discussing a subgroup analysis of the phase 3 ARANOTE trial assessing darolutamide + ADT in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback